{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T20:42:16Z","timestamp":1791751336678,"version":"4.3.4"},"reference-count":109,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T00:00:00Z","timestamp":1670457600000},"content-version":"vor","delay-in-days":3597,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1111\/jth.12075","type":"journal-article","created":{"date-parts":[[2012,12,27]],"date-time":"2012-12-27T04:40:54Z","timestamp":1356583254000},"page":"223-233","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":453,"title":["Coagulation and cancer: biological and clinical aspects"],"prefix":"10.1016","volume":"11","author":[{"given":"A.","family":"FALANGA","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"MARCHETTI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"VIGNOLI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1111\/jth.12075_bb0010","doi-asserted-by":"crossref","first-page":"4848","DOI":"10.1200\/JCO.2009.22.8197","article-title":"Venous thromboembolism in the hematologic malignancies","volume":"27","author":"Falanga","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1111\/jth.12075_bb0015","first-page":"673","article-title":"Clotting mechanisms and cancer: implications in thrombus formation and tumor progression","volume":"1","author":"Falanga","year":"2003","journal-title":"Clin Adv Hematol Oncol"},{"key":"10.1111\/jth.12075_bb0020","doi-asserted-by":"crossref","first-page":"115","DOI":"10.5482\/ha-1170","article-title":"Epidemiology, risk and outcomes of venous thromboembolism in cancer","volume":"32","author":"Falanga","year":"2012","journal-title":"Hamostaseologie"},{"key":"10.1111\/jth.12075_bb0025","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/978-0-387-79962-9_3","article-title":"Activation of clotting factors in cancer","volume":"148","author":"Rickles","year":"2009","journal-title":"Cancer Treat Res"},{"issue":"Suppl. 1","key":"10.1111\/jth.12075_bb0030","doi-asserted-by":"crossref","first-page":"S132","DOI":"10.1016\/S0049-3848(12)70033-6","article-title":"Microparticles in tumor progression","volume":"129","author":"Falanga","year":"2012","journal-title":"Thromb Res"},{"issue":"Suppl. 1","key":"10.1111\/jth.12075_bb0035","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/S0049-3848(12)70012-9","article-title":"Genetic pathways linking hemostasis and cancer","volume":"129","author":"Garnier","year":"2012","journal-title":"Thromb Res"},{"key":"10.1111\/jth.12075_bb0040","doi-asserted-by":"crossref","first-page":"I17","DOI":"10.1161\/01.CIR.0000078466.72504.AC","article-title":"Venous thromboembolism and cancer: risks and outcomes","volume":"107","author":"Lee","year":"2003","journal-title":"Circulation"},{"key":"10.1111\/jth.12075_bb0045","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S1470-2045(05)70207-2","article-title":"Cancer and venous thromboembolism","volume":"6","author":"Prandoni","year":"2005","journal-title":"Lancet Oncol."},{"key":"10.1111\/jth.12075_bb0050","doi-asserted-by":"crossref","first-page":"4919","DOI":"10.1200\/JCO.2009.22.3214","article-title":"Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action","volume":"27","author":"Khorana","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1111\/jth.12075_bb0055","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1182\/blood-2008-04-150250","article-title":"Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet","volume":"113","author":"Sanz","year":"2009","journal-title":"Blood"},{"key":"10.1111\/jth.12075_bb0060","doi-asserted-by":"crossref","first-page":"4839","DOI":"10.1200\/JCO.2009.22.3271","article-title":"Assessing risk of venous thromboembolism in the patient with cancer","volume":"27","author":"Khorana","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1111\/jth.12075_bb0065","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/leu.2011.314","article-title":"Venous thromboembolism in patients with essential thrombocythemia and polycythemia vera","volume":"26","author":"Reikvam","year":"2012","journal-title":"Leukemia"},{"key":"10.1111\/jth.12075_bb0070","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1177\/1358863X10388346","article-title":"Peripheral arterial ischemic events in cancer patients","volume":"16","author":"Sanon","year":"2011","journal-title":"Vasc Med"},{"key":"10.1111\/jth.12075_bb0075","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.thromres.2010.10.001","article-title":"Arterial thrombosis in ambulatory cancer patients treated with chemotherapy","volume":"127","author":"Di Nisio","year":"2011","journal-title":"Thromb Res"},{"key":"10.1111\/jth.12075_bb0080","first-page":"1250","article-title":"[Cerebrovascular disease in the cancer patient]","volume":"31","author":"Arboix","year":"2000","journal-title":"Rev Neurol"},{"key":"10.1111\/jth.12075_bb0085","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1038\/leu.2008.253","article-title":"Thrombosis in myeloproliferative disorders: pathogenetic facts and speculation","volume":"22","author":"Landolfi","year":"2008","journal-title":"Leukemia"},{"key":"10.1111\/jth.12075_bb0090","doi-asserted-by":"crossref","first-page":"5858","DOI":"10.1158\/1078-0432.CCR-11-0804","article-title":"Thrombotic microangiopathy with targeted cancer agents","volume":"17","author":"Blake\u2010Haskins","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1111\/jth.12075_bb0095","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1634\/theoncologist.2009-0067","article-title":"Cancer awareness in atypical thrombotic microangiopathies","volume":"14","author":"Oberic","year":"2009","journal-title":"Oncologist"},{"issue":"Suppl. 1","key":"10.1111\/jth.12075_bb0100","doi-asserted-by":"crossref","first-page":"S159","DOI":"10.1179\/102453312X13336169156735","article-title":"Thrombosis in stem cell transplantation","volume":"17","author":"Kansu","year":"2012","journal-title":"Hematology"},{"key":"10.1111\/jth.12075_bb0105","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.bbmt.2009.08.024","article-title":"Hepatic veno\u2010occlusive disease following stem cell transplantation: incidence, clinical course, and outcome","volume":"16","author":"Coppell","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1111\/jth.12075_bb0110","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1038\/sj.leu.2403004","article-title":"Defibrotide reduces procoagulant activity and increases fibrinolytic properties of endothelial cells","volume":"17","author":"Falanga","year":"2003","journal-title":"Leukemia"},{"key":"10.1111\/jth.12075_bb0115","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1002\/1097-0142(19860501)57:9<1846::AID-CNCR2820570925>3.0.CO;2-3","article-title":"Idiopathic deep vein thrombosis in an apparently healthy patient as a premonitory sign of occult cancer","volume":"57","author":"Aderka","year":"1986","journal-title":"Cancer"},{"key":"10.1111\/jth.12075_bb0120","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1182\/asheducation.V2010.1.150.3645826","article-title":"Evidence\u2010based mini\u2010review: should all patients with idiopathic venous thromboembolic events be screened extensively for occult malignancy?","volume":"2010","author":"Rosovsky","year":"2010","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1111\/jth.12075_bb0125","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1111\/j.1538-7836.2004.00720.x","article-title":"Extensive screening for occult malignant disease in idiopathic venous thromboembolism: a prospective randomized clinical trial","volume":"2","author":"Piccioli","year":"2004","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.12075_bb0130","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1538-7836.2010.04101.x","article-title":"Is extensive screening for cancer in idiopathic venous thromboembolism warranted?","volume":"9","author":"van Doormaal","year":"2011","journal-title":"J Thromb Haemost"},{"issue":"Suppl. 1","key":"10.1111\/jth.12075_bb0135","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.1016\/S0049-3848(12)70019-1","article-title":"Acquired hemophilia in malignancy","volume":"129","author":"Reeves","year":"2012","journal-title":"Thromb Res"},{"key":"10.1111\/jth.12075_bb0140","doi-asserted-by":"crossref","first-page":"6777","DOI":"10.1182\/blood-2010-11-297580","article-title":"How I treat the acquired von Willebrand syndrome","volume":"117","author":"Tiede","year":"2011","journal-title":"Blood"},{"key":"10.1111\/jth.12075_bb0145","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1055\/s-0037-1616139","article-title":"Disseminated intravascular coagulation in solid tumors: clinical and pathologic study","volume":"86","author":"Sallah","year":"2001","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.12075_bb0150","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1001\/archinte.160.6.809","article-title":"Risk factors for deep vein thrombosis and pulmonary embolism: a population\u2010based case\u2010control study","volume":"160","author":"Heit","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1111\/jth.12075_bb0155","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1200\/JCO.2005.03.8877","article-title":"Thromboembolism in hospitalized neutropenic cancer patients","volume":"24","author":"Khorana","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1111\/jth.12075_bb0160","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1182\/blood-2002-01-0108","article-title":"Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis","volume":"100","author":"Prandoni","year":"2002","journal-title":"Blood"},{"key":"10.1111\/jth.12075_bb0165","doi-asserted-by":"crossref","first-page":"601","DOI":"10.3171\/jns.2007.106.4.601","article-title":"Epidemiology of venous thromboembolism in 9489 patients with malignant glioma","volume":"106","author":"Semrad","year":"2007","journal-title":"J Neurosurg"},{"key":"10.1111\/jth.12075_bb0170","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.beha.2008.12.001","article-title":"Epidemiology of cancer\u2010related venous thromboembolism","volume":"22","author":"Wun","year":"2009","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1111\/jth.12075_bb0175","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1002\/cncr.23062","article-title":"Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients","volume":"110","author":"Khorana","year":"2007","journal-title":"Cancer"},{"key":"10.1111\/jth.12075_bb0180","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.thromres.2011.10.025","article-title":"Anticancer treatment and thrombosis","volume":"129","author":"Falanga","year":"2012","journal-title":"Thromb Res"},{"key":"10.1111\/jth.12075_bb0185","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1055\/s-2008-1079261","article-title":"Chemotherapy\u2010induced thrombosis: a role for microparticles and tissue factor?","volume":"34","author":"Lechner","year":"2008","journal-title":"Semin Thromb Hemost"},{"key":"10.1111\/jth.12075_bb0190","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.beha.2008.12.009","article-title":"Procoagulant mechanisms in tumour cells","volume":"22","author":"Falanga","year":"2009","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1111\/jth.12075_bb0195","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/j.1538-7836.2004.00607.x","article-title":"Characterization of the cell\u2010surface procoagulant activity of T\u2010lymphoblastoid cell lines","volume":"2","author":"Pickering","year":"2004","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.12075_bb0200","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1111\/j.1538-7836.2006.01985.x","article-title":"On the molecular mechanisms for the highly procoagulant pattern of C6 glioma cells","volume":"4","author":"Fernandes","year":"2006","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.12075_bb0205","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1055\/s-0037-1608919","article-title":"Heparanase induces tissue factor pathway inhibitor expression and extracellular accumulation in endothelial and tumor cells","volume":"99","author":"Nadir","year":"2008","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.12075_bb0210","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1002\/1097-0142(19940815)74:4<1367::AID-CNCR2820740430>3.0.CO;2-Y","article-title":"Application of cancer procoagulant as an early detection tumor marker","volume":"74","author":"Kozwich","year":"1994","journal-title":"Cancer"},{"key":"10.1111\/jth.12075_bb0215","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1080\/10245330701521416","article-title":"Procoagulant factors in patients with cancer","volume":"12","author":"Molnar","year":"2007","journal-title":"Hematology"},{"key":"10.1111\/jth.12075_bb0220","doi-asserted-by":"crossref","first-page":"210","DOI":"10.2302\/kjm.53.210","article-title":"New horizons in the analysis of circulating cell\u2010derived microparticles","volume":"53","author":"Horstman","year":"2004","journal-title":"Keio J Med"},{"key":"10.1111\/jth.12075_bb0225","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1538-7836.2010.04133.x","article-title":"Procoagulant myeloblast\u2010derived microparticles in AML patients: changes in numbers and thrombin generation potential during chemotherapy","volume":"9","author":"van Aalderen","year":"2011","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.12075_bb0230","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1160\/TH10-03-0187","article-title":"Microparticle\u2010associated tissue factor activity and venous thrombosis in multiple myeloma","volume":"105","author":"Auwerda","year":"2011","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.12075_bb0235","doi-asserted-by":"crossref","first-page":"911","DOI":"10.3324\/haematol.13774","article-title":"Elevated procoagulant microparticles expressing endothelial and platelet markers in essential thrombocythemia","volume":"94","author":"Trappenburg","year":"2009","journal-title":"Haematologica"},{"key":"10.1111\/jth.12075_bb0240","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/S0959-8049(02)00596-8","article-title":"Elevated levels of circulating platelet microparticles, VEGF, IL\u20106 and RANTES in patients with gastric cancer: possible role of a metastasis predictor","volume":"39","author":"Kim","year":"2003","journal-title":"Eur J Cancer"},{"key":"10.1111\/jth.12075_bb0245","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.leukres.2010.11.008","article-title":"The expression of annexin II and its role in the fibrinolytic activity in acute promyelocytic leukemia","volume":"35","author":"Liu","year":"2011","journal-title":"Leuk Res"},{"issue":"Suppl. 1","key":"10.1111\/jth.12075_bb0250","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/S0049-3848(12)70012-9","article-title":"Genetic pathways linking hemostasis and cancer","volume":"129","author":"Garnier","year":"2012","journal-title":"Thromb Res"},{"key":"10.1111\/jth.12075_bb0255","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1373\/clinchem.2009.123695","article-title":"Increased tissue factor expression is associated with reduced survival in non\u2010small cell lung cancer and with mutations of TP53 and PTEN","volume":"55","author":"Regina","year":"2009","journal-title":"Clin Chem"},{"key":"10.1111\/jth.12075_bb0260","first-page":"6966","article-title":"Spontaneous hematogenous and lymphatic metastasis, but not primary tumor growth or angiogenesis, is diminished in fibrinogen\u2010deficient mice","volume":"62","author":"Palumbo","year":"2002","journal-title":"Cancer Res"},{"issue":"Suppl. 1","key":"10.1111\/jth.12075_bb0265","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/S0049-3848(12)70013-0","article-title":"Platelet CLEC\u20102 and podoplanin in cancer metastasis","volume":"129","author":"Lowe","year":"2012","journal-title":"Thromb Res"},{"key":"10.1111\/jth.12075_bb0270","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1182\/blood-2004-06-2272","article-title":"Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell\u2010mediated elimination of tumor cells","volume":"105","author":"Palumbo","year":"2005","journal-title":"Blood"},{"key":"10.1111\/jth.12075_bb0275","doi-asserted-by":"crossref","first-page":"58S","DOI":"10.1378\/chest.124.3_suppl.58S","article-title":"Tissue factor, thrombin, and cancer","volume":"124","author":"Rickles","year":"2003","journal-title":"Chest"},{"key":"10.1111\/jth.12075_bb0280","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/S0049-3848(07)70125-1","article-title":"Tissue factor and PAR signaling in tumor progression","volume":"120","author":"Ruf","year":"2007","journal-title":"Thromb Res"},{"key":"10.1111\/jth.12075_bb0285","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1073\/pnas.94.2.663","article-title":"Constitutive production and thrombin\u2010induced release of vascular endothelial growth factor by human megakaryocytes and platelets","volume":"94","author":"Mohle","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1111\/jth.12075_bb0290","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1080\/0953710031000118876","article-title":"Time\u2010 and pH\u2010dependent release of PDGF and TGF\u2010beta from platelets in vitro","volume":"14","author":"Liu","year":"2003","journal-title":"Platelets"},{"key":"10.1111\/jth.12075_bb0295","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1161\/ATVBAHA.107.142539","article-title":"Role of protease activated receptor 1 and 2 signaling in hypoxia\u2010induced angiogenesis","volume":"27","author":"Uusitalo\u2010Jarvinen","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"Suppl. 1","key":"10.1111\/jth.12075_bb0300","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.1016\/S0049-3848(12)70020-8","article-title":"Tissue factor isoforms in cancer and coagulation: may the best isoform win","volume":"129","author":"Kocaturk","year":"2012","journal-title":"Thromb Res"},{"key":"10.1111\/jth.12075_bb0305","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1055\/s-0030-1267043","article-title":"Microparticles in cancer","volume":"36","author":"Rak","year":"2010","journal-title":"Semin Thromb Hemost"},{"key":"10.1111\/jth.12075_bb0310","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/j.1365-3083.2008.02139.x","article-title":"Ovarian cancer cells modulate human blood neutrophils response to activation in vitro","volume":"68","author":"Klink","year":"2008","journal-title":"Scand J Immunol"},{"key":"10.1111\/jth.12075_bb0315","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2147\/PROM.S10099","article-title":"Comparative assessment of low\u2010molecular\u2010weight heparins in cancer from the perspective of patient outcomes and survival","volume":"2","author":"Falanga","year":"2011","journal-title":"Patient Relat Outcome Meas"},{"key":"10.1111\/jth.12075_bb0320","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1200\/JCO.2009.22.4584","article-title":"Impact of venous thromboembolism and anticoagulation on cancer and cancer survival","volume":"27","author":"Kuderer","year":"2009","journal-title":"J Clin Oncol"},{"issue":"Suppl. 1","key":"10.1111\/jth.12075_bb0325","doi-asserted-by":"crossref","first-page":"S114","DOI":"10.1016\/S0049-3848(12)70029-4","article-title":"Low\u2010molecular\u2010weight heparin and survival in lung cancer","volume":"129","author":"Noble","year":"2012","journal-title":"Thromb Res"},{"key":"10.1111\/jth.12075_bb0330","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1200\/JCO.2010.31.9293","article-title":"Randomized trial of the effect of the low molecular weight heparin nadroparin on survival in patients with cancer","volume":"29","author":"van Doormaal","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1111\/jth.12075_bb0335","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1186\/1471-2407-8-361","article-title":"Rationale and design of PROSPECT\u2010CONKO 004: a prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy)","volume":"8","author":"Riess","year":"2008","journal-title":"BMC Cancer"},{"key":"10.1111\/jth.12075_bb0340","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S1359-6349(09)71225-X","article-title":"Gemcitabine with or without prophylactic weight\u2010adjusted dalteparin in patients with advanced or metatastatic pancreatic cancer (APC): a multicentre, randomised phase IIB trial (the UK FRAGEM study)","volume":"7","author":"Maraveyas","year":"2009","journal-title":"Eur J Cancer Suppl"},{"key":"10.1111\/jth.12075_bb0345","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1186\/1471-2407-9-355","article-title":"FRAGMATIC: a randomised phase III clinical trial investigating the effect of fragmin added to standard therapy in patients with lung cancer","volume":"9","author":"Griffiths","year":"2009","journal-title":"BMC Cancer"},{"issue":"Suppl. 1","key":"10.1111\/jth.12075_bb0350","doi-asserted-by":"crossref","first-page":"S80","DOI":"10.1016\/S0049-3848(12)70022-1","article-title":"The protein C pathway in cancer metastasis","volume":"129","author":"Spek","year":"2012","journal-title":"Thromb Res"},{"issue":"Suppl. 1","key":"10.1111\/jth.12075_bb0355","doi-asserted-by":"crossref","first-page":"S119","DOI":"10.1016\/S0049-3848(12)70030-0","article-title":"Mechanisms coupling thrombomodulin to tumor dissemination","volume":"129","author":"Horowitz","year":"2012","journal-title":"Thromb Res"},{"key":"10.1111\/jth.12075_bb0360","series-title":"Cancer\u2010Associated Thrombosis: New Findings in Translational Science, Prevention, and Treatment","first-page":"131","article-title":"Venous thromboembolism in hematologic malignancies","author":"Falanga","year":"2008"},{"key":"10.1111\/jth.12075_bb0365","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1056\/NEJMoa035572","article-title":"Efficacy and safety of low\u2010dose aspirin in polycythemia vera","volume":"350","author":"Landolfi","year":"2004","journal-title":"N Engl J Med"},{"issue":"Suppl. 2","key":"10.1111\/jth.12075_bb0370","doi-asserted-by":"crossref","first-page":"S128","DOI":"10.1016\/S0049-3848(10)70030-X","article-title":"The National Comprehensive Cancer Center Network (NCCN) guidelines on the management of venous thromboembolism in cancer patients","volume":"125","author":"Streiff","year":"2010","journal-title":"Thromb Res"},{"key":"10.1111\/jth.12075_bb0375","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.critrevonc.2006.05.001","article-title":"Venous thromboembolism and cancer: guidelines of the Italian Association of Medical Oncology (AIOM)","volume":"59","author":"Mandala","year":"2006","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1111\/jth.12075_bb0380","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.critrevonc.2008.12.004","article-title":"2008 French national guidelines for the treatment of venous thromboembolism in patients with cancer: report from the working group","volume":"73","author":"Farge","year":"2010","journal-title":"Crit Rev Oncol Hematol"},{"issue":"Suppl. 6","key":"10.1111\/jth.12075_bb0385","doi-asserted-by":"crossref","first-page":"vi85","DOI":"10.1093\/annonc\/mdr392","article-title":"Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines","volume":"22","author":"Mandala","year":"2011","journal-title":"Ann Oncol"},{"issue":"Suppl. 2","key":"10.1111\/jth.12075_bb0390","doi-asserted-by":"crossref","first-page":"S120","DOI":"10.1016\/S0049-3848(10)70029-3","article-title":"Prevention and treatment of venous thromboembolism among patients with cancer: the American Society of Clinical Oncology Guidelines","volume":"125","author":"Lyman","year":"2010","journal-title":"Thromb Res"},{"key":"10.1111\/jth.12075_bb0395","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa012385","article-title":"Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer","volume":"346","author":"Bergqvist","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.12075_bb0400","doi-asserted-by":"crossref","first-page":"e171","DOI":"10.1016\/j.thromres.2011.09.002","article-title":"Prevention of venous thromboembolism in patients with cancer: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET)(1)","volume":"129","author":"Siragusa","year":"2012","journal-title":"Thromb Res"},{"key":"10.1111\/jth.12075_bb0405","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.ejca.2011.10.017","article-title":"Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer","volume":"48","author":"Maraveyas","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1111\/jth.12075_bb0410","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S1470-2045(09)70232-3","article-title":"Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo\u2010controlled, double\u2010blind study","volume":"10","author":"Agnelli","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1111\/jth.12075_bb0415","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa1108898","article-title":"Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer","volume":"366","author":"Agnelli","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.12075_bb0420","doi-asserted-by":"crossref","first-page":"714","DOI":"10.6004\/jnccn.2011.0062","article-title":"Venous thromboembolic disease","volume":"9","author":"Streiff","year":"2011","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1111\/jth.12075_bb0425","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1182\/asheducation-2007.1.165","article-title":"Management of Thrombohemorrhagic Syndromes (THS) in hematologic malignancies","author":"Falanga","year":"2007","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1111\/jth.12075_bb0430","doi-asserted-by":"crossref","first-page":"4063","DOI":"10.1200\/JCO.2005.10.192","article-title":"Randomized placebo\u2010controlled study of low\u2010dose warfarin for the prevention of central venous catheter\u2010associated thrombosis in patients with cancer","volume":"23","author":"Couban","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1111\/jth.12075_bb0435","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/j.1365-2141.2005.05529.x","article-title":"Incidence of thrombotic complications in patients with haematological malignancies with central venous catheters: a prospective multicentre study","volume":"129","author":"Cortelezzi","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1111\/jth.12075_bb0440","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1538-7836.2011.04215.x","article-title":"Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta\u2010analysis","volume":"9","author":"Carrier","year":"2011","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.12075_bb0445","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1200\/JCO.2010.31.6844","article-title":"Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open\u2010label, randomized trial","volume":"29","author":"Palumbo","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1111\/jth.12075_bb0450","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1182\/blood-2011-03-344333","article-title":"Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide","volume":"119","author":"Larocca","year":"2012","journal-title":"Blood"},{"key":"10.1111\/jth.12075_bb0455","doi-asserted-by":"crossref","first-page":"5490","DOI":"10.1200\/JCO.2007.14.1283","article-title":"American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer","volume":"25","author":"Lyman","year":"2007","journal-title":"J Clin Oncol"},{"issue":"Suppl. 5","key":"10.1111\/jth.12075_bb0460","doi-asserted-by":"crossref","first-page":"v274","DOI":"10.1093\/annonc\/mdq199","article-title":"Venous thromboembolism in cancer patients: ESMO Clinical Practice Guidelines for the management","volume":"21","author":"Mandala","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1111\/jth.12075_bb0465","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/sj.leu.2405062","article-title":"Prevention of thalidomide\u2010 and lenalidomide\u2010associated thrombosis in myeloma","volume":"22","author":"Palumbo","year":"2008","journal-title":"Leukemia"},{"key":"10.1111\/jth.12075_bb0470","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","article-title":"Development and validation of a predictive model for chemotherapy\u2010associated thrombosis","volume":"111","author":"Khorana","year":"2008","journal-title":"Blood"},{"key":"10.1111\/jth.12075_bb0475","doi-asserted-by":"crossref","first-page":"5377","DOI":"10.1182\/blood-2010-02-270116","article-title":"Prediction of venous thromboembolism in cancer patients","volume":"116","author":"Ay","year":"2010","journal-title":"Blood"},{"key":"10.1111\/jth.12075_bb0480","doi-asserted-by":"crossref","first-page":"6830","DOI":"10.1158\/1078-0432.CCR-09-0371","article-title":"Tumor\u2010derived tissue factor\u2010bearing microparticles are associated with venous thromboembolic events in malignancy","volume":"15","author":"Zwicker","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1111\/jth.12075_bb0485","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1001\/archinte.162.15.1729","article-title":"Comparison of low\u2010molecular\u2010weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study","volume":"162","author":"Meyer","year":"2002","journal-title":"Arch Intern Med"},{"key":"10.1111\/jth.12075_bb0490","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJMoa025313","article-title":"Low\u2010molecular\u2010weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer","volume":"349","author":"Lee","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.12075_bb0495","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1177\/1076029606293692","article-title":"Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180\u2010day period","volume":"12","author":"Deitcher","year":"2006","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1111\/jth.12075_bb0500","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.amjmed.2006.02.022","article-title":"Long\u2010term low\u2010molecular\u2010weight heparin versus usual care in proximal\u2010vein thrombosis patients with cancer","volume":"119","author":"Hull","year":"2006","journal-title":"Am J Med"},{"key":"10.1111\/jth.12075_bb0505","doi-asserted-by":"crossref","first-page":"454S","DOI":"10.1378\/chest.08-0658","article-title":"Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence\u2010Based Clinical Practice Guidelines (8th Edition)","volume":"133","author":"Kearon","year":"2008","journal-title":"Chest"},{"key":"10.1111\/jth.12075_bb0510","doi-asserted-by":"crossref","first-page":"3078","DOI":"10.1200\/JCO.2000.18.17.3078","article-title":"Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis","volume":"18","author":"Hutten","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1111\/jth.12075_bb0515","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/j.1538-7836.2009.03326.x","article-title":"Dose escalation of low molecular weight heparin to manage recurrent venous thromboembolic events despite systemic anticoagulation in cancer patients","volume":"7","author":"Carrier","year":"2009","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.12075_bb0520","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1517\/14656566.2010.494181","article-title":"Treatment of thromboembolism in cancer patients","volume":"11","author":"Panova\u2010Noeva","year":"2010","journal-title":"Expert Opin Pharmacother"},{"key":"10.1111\/jth.12075_bb0525","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","article-title":"Dabigatran versus warfarin in the treatment of acute venous thromboembolism","volume":"361","author":"Schulman","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.12075_bb0530","unstructured":"Buller H. EINSTEIN. European Society of Cardiology. Sep 2010 meeting 2010."},{"issue":"Suppl. 1","key":"10.1111\/jth.12075_bb0535","doi-asserted-by":"crossref","first-page":"S101","DOI":"10.1016\/S0049-3848(12)70027-0","article-title":"New and old anticoagulants in cancer","volume":"129","author":"Verso","year":"2012","journal-title":"Thromb Res"},{"key":"10.1111\/jth.12075_bb0540","doi-asserted-by":"crossref","first-page":"e2011068","DOI":"10.4084\/mjhid.2011.068","article-title":"Pathogenesis and treatment of thrombohemorrhagic diathesis in acute promyelocytic leukemia","volume":"3","author":"Falanga","year":"2011","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"Suppl. 1","key":"10.1111\/jth.12075_bb0545","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1159\/000073283","article-title":"All\u2010trans\u2010retinoic acid and bleeding\/thrombosis","volume":"33","author":"Falanga","year":"2003","journal-title":"Pathophysiol Haemost Thromb"},{"key":"10.1111\/jth.12075_bb0550","doi-asserted-by":"crossref","first-page":"3395","DOI":"10.1182\/blood-2007-07-100669","article-title":"Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all\u2010trans retinoic acid and idarubicin","volume":"111","author":"de la Serna","year":"2008","journal-title":"Blood"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjth.12075","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjth.12075","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622111141?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622111141?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/jth.12075\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T03:05:37Z","timestamp":1761534337000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783622111141"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2]]},"references-count":109,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["S1538783622111141"],"URL":"https:\/\/doi.org\/10.1111\/jth.12075","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2013,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Coagulation and cancer: biological and clinical aspects","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/jth.12075","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}